NeuroDerm Presents Results of Continuous Subcutaneous Administration of Levodopa/Carbidopa Trials

(October 29, 2014) – NeuroDerm Ltd. announced that top-line results for ND0612L from a phase II study in patients with moderate Parkinson’s patients, and preliminary interim results from a phase IIA study of ND0612H and ND0612L in advanced Parkinson’s patients, will be presented at The Michael J. Fox Foundation’s 2014 Parkinson’s Disease Therapeutics Conference, today in New York, NY.

This research, Continuous Subcutaneous Administration of Levodopa/Carbidopa (ND0612) for the Treatment of Parkinson’s Disease, is partially funded with a grant from the Parkinson’s Unity Walk. Read more…